Case study

Webinar: Are you ready for FDA questions about impurities?

Sep 2020, by Ejvind Mortz

monitor impurities and ensure consistent gene therapies

Are you submitting an IND for a Human Gene Therapy?

The guidelines state that you should characterize impurities and monitor process performance parameters for process consistency.

But what if no good impurity ELISA is available?

In just 30 minutes we show you how to

  • select the best ELISA for your project
  • use mass spectrometry to quantify all protein impurities

Talk to us

Whatever protein-related challenge or question you may have, we would love to help. Our experts can help you decide on the best analytical approach for your project by email or online meeting - providing advice without obligation.

I would like an
Hidden
Hidden
Hidden
This field is for validation purposes and should be left unchanged.